DNDI-6174

• CAT Number: I040150
• CAS Number: 2868298-43-3
• Molecular Formula: C16H13N5O2
• Molecular Weight: 307.31
• Purity: ≥95%
• Synonyms: 7-(2-amino-4,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-benzodioxole-4-carbonitrile
• InChI: InChI=1S/C16H13N5O2/c1-7-11(12-8(2)20-16(18)21-15(12)19-7)10-4-3-9(5-17)13-14(10)23-6-22-13/h3-4H,6H2,1-2H3,(H3,18,19,20,21)
• InChIKey: UFCPCEFCXDROHW-UHFFFAOYSA-N
• SMILES: CC1=C(C2=C(N=C(N=C2N1)N)C)C3=C4C(=C(C=C3)C#N)OCO4

DNDI-6174 (Cat No.: I040150) is an investigational compound developed by the Drugs for Neglected Diseases initiative (DNDi) as a potential treatment for leishmaniasis, a parasitic disease caused by Leishmania species. It is part of a series of nitroimidazole-based drug candidates with antiparasitic activity. DNDI-6174 works by disrupting parasite-specific metabolic pathways, showing promise in preclinical models for efficacy and safety. The compound aims to provide an affordable, oral, and well-tolerated alternative to current treatments, which often involve toxic or complex regimens unsuitable for endemic regions.

Reference

[1]. Stéphanie Braillard, et al. DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1. Sci Transl Med. 2023 Dec 13;15(726):eadh9902.
[Content Brief]